A Phase 3 interventional study of Levopront® syrup 30 mg/5 ml and Libexin® in Cough, sponsored by Dompé Farmaceutici S.p.A. Completed at 8 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Dompé Farmaceutici S.p.A · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective:
To assess the efficacy of Levopront® in comparison with Libexin® based on daytime cough resolution rate by Day 8.
The daytime cough symptoms resolution corresponds to 0 or 1 points on the "Six-point daytime and nighttime cough assessment scale".
Secondary objectives:
Treatment effect assessment in terms of the following efficacy and safety parameters:
This is a multicenter, open-label, randomized, clinical trial to assess the efficacy and safety of Levopront® syrup 30 mg/5 ml in comparison with Libexin® 100 mg tablets in patients suffering from dry non-productive cough caused by acute upper respiratory infection
428 studies on the registry are indexed under Cough; 68 are open to participants now.
This study's enrollment of 184 is above the median of 80 across 320 interventional studies indexed under Cough.
Browse Cough studies →Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects should meet the following inclusion criteria to be included into this clinical trial:
Patient's consent to use the adequate methods throughout the study period. The adequate birth control methods are as follows:
Exclusion Criteria:
Subjects with any of the following conditions will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml (60 mg) t.i.d. for 7 days. The study drugs was taken 3 times a day, at intervals of at least 6 hours, between meals for 7 days.
Drug: Levopront® syrup 30 mg/5 ml
Libexin® (prenoxdiazine) 100 mg tablets. Libexin® was administered orally, 1 tablet (100 mg) 3 times a day for 7 days.
Drug: Libexin®
Drug page: Dipropizine
The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
Also known as: levodropropizine
The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
Also known as: prenoxdiazine
Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population
Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
Time frame: At Visit 3, Day 8
Number of Participants With Daytime Cough Resolution Rate by Day 8 in the ITT Population
Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
Time frame: At Visit 3, Day 8
Number of Participants With Nighttime Cough Resolution Rate by Day 8 in the ITT Population
Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The nighttime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
Time frame: At Visit 3, Day 8
Number of Participants With Daytime & Nighttime Cough Symptoms Resolution in the ITT Population
Daytime cough ( \>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The (daytime and nighttime) cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 4 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
Time frame: At Visit 2, Day 4
Change From Baseline in Severity and Frequency of Daytime and Nighttime Cough According to "Six-point Daytime and Nighttime Cough Assessment Scale" in the ITT Population
Daytime cough ( \>08:00 h up to 22:00 h) evaluated on a 6-point scale: 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) evaluated on a 6-point scale: 0 = no cough during the night to 5 = distressing coughs preventing any sleep.
Time frame: Baseline, At visit 2 Day 4; at visit 3, Day 8
Change From Baseline in Cough Intensity According to the Visual-analogue Scale (VAS) in the ITT Population.
The visual-analogue scale (VAS) is a 100 mm scale which ranges from 'no cough' (0 mm) to 'the worst cough severity' (100 mm). The higher the score, the worse the outcome.
Time frame: Baseline, At visit 2 (Day 4); at visit 3 (Day 8)
Change From Baseline in Pre-bronchodilator FEV1 Values on Day 8 in the ITT Population.
FEV1 is the Forced Expiratory Volume (in liters) in 1 second. The higher the value, the better the outcome.
Time frame: At Visit 3 (Day 8)
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) of the Various Severity According to Subjective Complaints
Adverse Event (AE) - any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, complaint or disorder. Serious Adverse Event (SAE) - Any adverse medical event which, irrespective of the dose of the study drug: * results in death; * is life-threatening; * requires hospitalization (initial or prolonged); * results in significant, persistent or permanent impairment or disability; or * is a congenital anomaly or birth defect * is an important medical event that may be not immediately life threatening or result in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definition above.
Time frame: From the moment of signing Informed Consent Form (prior to administration of the first dose of the study drug) to Day 30 after the last visit of the patient or last procedure per protocol, up to day 10"
Totally, 184 patients were randomized into Levopront® (Test) and the Libexin® (Control) treatment groups: there were 92 patients in each group. All the patients completed the study according to the protocol. One patient was screen failure due to post-bronchodilator FEV1 increase.
| Milestone | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Started | 92 | 92 |
| Itt population | 92 | 92 |
| Pp population | 88 | 91 |
| Safety population | 92 | 92 |
| Completed | 92 | 92 |
| Not completed | 0 | 0 |
Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
| Participants | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Resolved (<2) | 67 | 64 |
| Ongoing (≥2) | 21 | 27 |
Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
| Participants | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Resolved (<2) | 70 | 65 |
| Ongoing (≥2) | 22 | 27 |
Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The nighttime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
| Participants | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Resolved (<2) | 90 | 89 |
| Ongoing (≥2) | 2 | 3 |
Daytime cough ( \>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The (daytime and nighttime) cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 4 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.
| Participants | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Resolved (<2) | 22 | 20 |
| Ongoing (≥2) | 70 | 72 |
Daytime cough ( \>08:00 h up to 22:00 h) evaluated on a 6-point scale: 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) evaluated on a 6-point scale: 0 = no cough during the night to 5 = distressing coughs preventing any sleep.
| units on a scale | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| daytime cough score at Visit 2, Day 4 | -1.2 ± 0.8 | -1.2 ± 0.6 |
| daytime cough score at Visit 3, Day 8 | -2.5 ± 0.8 | -2.2 ± 0.7 |
| nighttime cough score at Visit 2, Day 4 | -0.9 ± 0.8 | -1.0 ± 0.9 |
| nighttime cough score at Visit 3, Day 8 | -1.9 ± 1.1 | -1.9 ± 1.0 |
The visual-analogue scale (VAS) is a 100 mm scale which ranges from 'no cough' (0 mm) to 'the worst cough severity' (100 mm). The higher the score, the worse the outcome.
| units on a scale | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Visit 2, Day 4 | -28.9 ± 15.0 | -24.9 ± 15.0 |
| Visit 3, Day 8 | -52.1 ± 18.1 | -44.6 ± 17.8 |
FEV1 is the Forced Expiratory Volume (in liters) in 1 second. The higher the value, the better the outcome.
| liters | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| Change From Baseline in Pre-bronchodilator FEV1 Values on Day 8 in the ITT Population. | 0.0 ± 0.6 | 0.1 ± 0.4 |
Adverse Event (AE) - any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, complaint or disorder. Serious Adverse Event (SAE) - Any adverse medical event which, irrespective of the dose of the study drug: * results in death; * is life-threatening; * requires hospitalization (initial or prolonged); * results in significant, persistent or permanent impairment or disability; or * is a congenital anomaly or birth defect * is an important medical event that may be not immediately life threatening or result in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definition above.
| Participants | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| patients with AE/SAE | 14 | 12 |
| patients with SAE | 0 | 0 |
| Patients with death outcome AE/SAE | 0 | 0 |
| Patients with mild and moderate AE/SAE | 14 | 12 |
| Patients with severe AE/SAE | 0 | 0 |
| Patients with related (possible, probable or highly probable) AE/SAE | 1 | 2 |
| Patients with AE/SAE led to discontinuation | 0 | 0 |
Collected over At visits 1 (day 1), 2 (day 4), 3 (Day 8) and follow-up (telephon call), up to day 10. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levopront® Syrup 30 mg/5 ml | 0/92 (0%) | 0/92 (0%) | 14/92 (15.2%) |
| Libexin® 100 mg Tablets | 0/92 (0%) | 0/92 (0%) | 12/92 (13%) |
| Event | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets |
|---|---|---|
| HeadacheNervous system disorders | 5/92 | 4/92 |
| Dry mouthGastrointestinal disorders | 2/92 | 4/92 |
| Alanine aminotransferase increasedInvestigations | 2/92 | 1/92 |
| Hypoaesthesia oralGastrointestinal disorders | 1/92 | 0/92 |
| NauseaGastrointestinal disorders | 1/92 | 0/92 |
| GastroduodenitisGastrointestinal disorders | 0/92 | 1/92 |
| Abdominal painGastrointestinal disorders | 0/92 | 1/92 |
| DizzinessNervous system disorders | 1/92 | 0/92 |
| DysgeusiaNervous system disorders | 0/92 | 1/92 |
| MalaiseGeneral disorders | 1/92 | 0/92 |
ITT population consisted of all randomized patients from both treatment groups.
| Age, Categorical(Participants) | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 92 | 92 | 184 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets | Total |
|---|---|---|---|
| Mean | 40.2 ± 11.4 | 40.2 ± 13.4 | 40.2 ± 12.42 |
| Sex: Female, Male(Participants) | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets | Total |
|---|---|---|---|
| Female | 60 | 64 | 124 |
| Male | 32 | 28 | 60 |
| Race (NIH/OMB)(Participants) | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 92 | 92 | 184 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Levopront® Syrup 30 mg/5 ml | Libexin® 100 mg Tablets | Total |
|---|---|---|---|
| Russia | 92 | 92 | 184 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Mar 2018, 15 months.
Results were first posted in Apr 2024, 6 years 1 month after primary completion.
Of 18 phase 3 interventional studies under Cough, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dipropizine